(RTTNews) - Implantica AG (8IM1.F) announced its interim results for the second quarter and first half of 2026, highlighting strong sales growth, improved margins, and reduced operating losses compared to the same period last year, alongside a pivotal FDA approval for RefluxStop.

Net sales for Q2 2026 rose to EUR 717,000, a 66% increase from EUR 433,000 in Q2 2025, driven by expanding adoption of RefluxStop across Europe and preparations for the U.S. launch.

Gross margin improved to 94% from 90% last year, reflecting favorable product mix and manufacturing efficiencies. Operating loss narrowed to EUR -4.2 million from EUR -4.5 million in Q2 2025, while loss after tax improved to EUR -3.98 million compared to EUR -5.45 million.

Earnings per share came in at EUR -0.06 versus EUR -0.08 in the prior year quarter.

For the first half of 2026, net sales reached EUR 1.57 million, up 34% from EUR 1.17 million in H1 2025.

Operating loss was EUR -8.06 million, reduced from -8.69 million, while loss after tax remained broadly stable at EUR -8.27 million compared to EUR -8.21 million last year.

EPS stood at EUR -0.21, unchanged from H1 2025.

Cash and cash equivalents totaled EUR 41.7 million at the end of June 2026.

The quarter was marked by the FDA's approval of RefluxStop, Implantica's flagship device for acid reflux, positioning the company for commercial launch in the U.S.

Management also highlighted new clinical evidence published in Nature's Scientific Reports, confirming long-term safety, with serious adverse events below 2%.

Expansion in Europe continued with over 60 Center of Excellence established, including MD Anderson Madrid and new Centers in Switzerland and the UK.

8IM1.F has traded between EUR 3.62 and EUR 6.67 over the past year. The stock is currently trading at EUR 5.38, up 11.04%.